Name

Besremi

Alternate Names

Ropeginterferon alfa-2b-njft

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

none

NSC Number

None

Primary Site

None

Histology

Polycythemia vera

Remarks

November 15, 2021 The FDA approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera. Besremi is the first FDA-approved medication for polycythemia vera that patients can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera.

Coding

This drug should be coded
Glossary